Workflow
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of 148.4Million,DrivenbyContinuedFIRDAPSE®Growth,StrongAGAMREE®UptakeandGrowth,andContinuedDemandforFYCOMPA®RaisingFullYear2025TotalRevenueGuidancetobetween148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between 565 Million and 585Million,ReflectingBetterthanOriginallyForecastedPerformanceRecentlyAnnouncedShareRepurchaseProgramofupto585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to 200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, F ...